310. Congenital anomalies syndrome Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 11 Drugs : 20 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 7

Drugs and their primary sponsors and trial info
Antioxidants   
   University of Colorado, Denver
      2008   Phase 2   NCT01773278   United States;
Cholesterol   
   University of Colorado, Denver
      2008   Phase 2   NCT01773278   United States;
Cholesterol supplementation   
   Oregon Health and Science University
      2011   -   NCT01356420   United States;
Cholic Acid   
   University of Nebraska
      2021   Phase 1/Phase 2   NCT03720990   United States;
Crystalline cholesterol oil-based suspension   
   Boston Children’s Hospital
      1998   Phase 1/Phase 2   NCT00272844   United States;
DHC   
   Obstetrics and Gynecology Hospital Affiliated to Fudan University
      2020   Phase 0   ChiCTR2000035477   China;
Egg substitute, without cholesterol   
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2005   Phase 2   NCT00114634   United States;
Egg yolk preparation with cholesterol   
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2005   Phase 2   NCT00114634   United States;
Gold   
   Obstetrics and Gynecology Hospital Affiliated to Fudan University
      2020   Phase 0   ChiCTR2000035477   China;
Lactose   
   Oregon Health and Science University
      2011   -   NCT01434745   United States;
Lovastatin   
   Northwestern University
      2011   Phase 2   NCT01110642   United States;
N-acetyl cysteine   
   Johns Hopkins University
      2022   Phase 2   NCT04381897   United States;
OraPlus   
   Forbes Porter, M.D.
      2003   Phase 2   NCT00064792   United States;
Simvastatin   
   Oregon Health and Science University
      2011   -   NCT01434745   United States;
Simvastatin Susp.   
   Forbes Porter, M.D.
      2003   Phase 2   NCT00064792   United States;